First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Biogen Inc.

    BIIB · 40 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 40 macro, policy, and market developments to Biogen Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for BIIB yet, so no modelled value is shown. The BIIB valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run BIIB on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for BIIB. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

      Increased investor interest in companies with strong neuroscience and rare disease pipelines, potential for future pipeline expansion or partnerships in cardiovascular diseases.

      · Moves probability of success pipeline, addressable market size, r&d efficiency

    • Main threat

      FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

      Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza.

      · Moves peak sales estimates for spinraza, market share assumptions for spinraza, pricing power for existing sma therapies

    • Open question

      Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms

      Increased competition in neurodegenerative disease space, potential for new therapeutic approaches to influence R&D strategies.

      · Moves pipeline valuation, future r&d spend

    What changed, by assumption

    Probability of success pipeline
    • 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    Peak sales estimates for spinraza
    • 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    • 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
    Market share projections for existing ms portfolio (e.g., tecfidera, vumerity, tysabri)
    • 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
    Market share for existing ms drugs (e.g., tecfidera, vumerity)
    • 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
    Market share projections for ms portfolio (e.g., tecfidera, vumerity, tysabri)
    • 2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Datawatch3-12m0.10
    2026-09-29Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review Voucherwatch3-12m0.20
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Sharewatch3-12m0.20
    2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseasewatch3-12m0.40
    2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapieswatch3-12m0.30
    2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programswatch3-12m0.30
    2026-09-23Roche to Acquire Ionis Pharmaceuticals, Inc.watch3-12m0.30
    2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenBearish3-12m0.20
    2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targetswatch3-12m0.20
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksBearish1-3m0.30
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksBearish3-12m0.20
    2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksBearish3-12m0.30